Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Granisetron transdermal - Abeille Pharmaceuticals

Next Previous
Drug Profile

Granisetron transdermal - Abeille Pharmaceuticals

Alternative Names: AB-1001; Granisetron transdermal - Abeille; Inno-P08002; SyB D-0701; SyB-0701

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abeille Pharmaceuticals
  • Developer Abeille Pharmaceuticals; INNOPHARMAX; SymBio Pharmaceuticals
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chemotherapy-induced nausea and vomiting
  • Phase II Radiotherapy-induced nausea and vomiting

Most Recent Events

  • 06 Aug 2020 Kyowa Kirin withdraws a phase II trial in Gastroparesis in USA (Transdermal) due to limited resources (NCT04501211)
  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 01 Jun 2015 Phase III development is ongoing

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top